Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866267 · ClinicalTrials.gov registry record · Phase 4
Switching Undetectables to Selzentry
A Phase 4 study of Human Immunodeficiency Virus and AIDS, sponsored by St. Hope Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01866267: Completed Phase 4 study of Human Immunodeficiency Virus and AIDS, sponsored by St. Hope Foundation.
NCT01866267 is a Phase 4 study of Human Immunodeficiency Virus and AIDS that has completed, run by St. Hope Foundation. The registered enrollment target is 31 participants, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866267, a Phase 4 study of Human Immunodeficiency Virus and AIDS, has completed, sponsored by St. Hope Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)\] and switch them to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs.
Primary Outcome
Percentage of HIV positive patients with Undetectable Viral load (HIV-1 RNA \< 100 copies/mL) on once-daily Selzentry plus 2 NRTI
Conditions Studied
Interventions
- DRUG Maraviroc
Study Locations (1)
Texas
- St. Hope Foundation, Inc. - Bellaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
What the finished NCT01866267 record still lists
NCT01866267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 183-participant average among 39 other Human Immunodeficiency Virus trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Human Immunodeficiency Virus appearing as the primary indexed condition, and to 1 intervention - of which Maraviroc is the first listed.
NCT01866267 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01866267 about?
NCT01866267 is a clinical study titled "Switching Undetectables to Selzentry". This pilot single arm, single site, open-labeled switch study seeks to enroll thirty (30) HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen \[Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibito...
What is the current status of trial NCT01866267?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2013-01. Estimated completion is 2014-06.
What conditions does trial NCT01866267 study?
This clinical trial studies the following conditions: Human Immunodeficiency Virus, AIDS.
What interventions are being tested in trial NCT01866267?
The interventions under investigation include: Maraviroc (DRUG).
Who is sponsoring clinical trial NCT01866267?
This trial is sponsored by St. Hope Foundation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01866267 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Immunodeficiency Virus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01866267's enrollment target sits among peer trials
31 26th of 39 higher than 14 of 39 other Human Immunodeficiency Virus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Human Immunodeficiency Virus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Low Dose Naltrexone for Pain in Patients With HIV
RECRUITING · Phase 4
-
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV
RECRUITING · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
-
Post-Exposure Prophylaxis in Health Care Workers
COMPLETED · Phase 4
-
Biomarkers for Event-driven PrEP Adherence
COMPLETED · Phase 4
-
HIV Non-Occupational Post-Exposure Prophylaxis
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia